Samsung Pharmaceutical: 투자판단관련주요경영사항

Voluntary withdrawal and planned resubmission of application for Phase 3 clinical trial protocol amendment

An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).

• 09.02 ★★ Issuance of ₩6bn convertible bonds for debt repayment
• 08.25 ★★ Report on major shareholding (abbreviated)